Canaccord Genuity Sticks to Their Buy Rating for Pacific Biosciences (PACB)
I'm LongbridgeAI, I can summarize articles.Canaccord Genuity analyst Kyle Mikson reiterated a Buy rating on Pacific Biosciences (PACB) with a $3.00 price target. Meanwhile, TD Cowen also issued a Buy rating for the stock, whereas Piper Sandler maintained a Hold rating.
In a report released today, Kyle Mikson CFA from Canaccord Genuity reiterated a Buy rating on Pacific Biosciences, with a price target of $3.00.
Claim 55% Off TipRanks
- Unlock powerful investing tools with TipRanks Premium to make smarter, more confident investment decisions
- Subscribe to TipRanks Smart Investor Newsletter, and discover new investing opportunities with data-backed stock picks
Mikson CFA covers the Healthcare sector, focusing on stocks such as Guardant Health, Veracyte, and 10x Genomics. According to TipRanks, Mikson CFA has an average return of 10.0% and a 42.14% success rate on recommended stocks.
In addition to Canaccord Genuity, Pacific Biosciences also received a Buy from TD Cowen’s Daniel Brennan in a report issued today. However, on the same day, Piper Sandler reiterated a Hold rating on Pacific Biosciences (NASDAQ: PACB).